Glenmark Life Sciences signs Master Supply Agreement with a leading Japanese pharmaceutical company to manufacture and supply API in the therapeutic area of Urinary Anti-Spasmodic, with estimated commercial value of $5 million.
AI Assistant
Glenmark Life Sciences Ltd
2024
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.